share_log

8-K: Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

8-K: Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

8-K：Cingulate公佈2024年第二季度財務業績，並提供已實現的重大里程碑的最新發展情況
美股SEC公告 ·  08/13 08:02

Moomoo AI 已提取核心訊息

On August 13, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, and provided updates on its clinical and business developments. The company reported significant progress with its lead product candidate, CTx-1301, for the treatment of ADHD, including FDA clearance to file for marketing approval and the completion of registration batches, which are essential for a New Drug Application (NDA) submission targeted for the first half of 2025. Cingulate also completed a payer study to assess the market potential for CTx-1301 and raised $1.6 million through a warrant inducement. Additionally, the company executed a one-for-twelve reverse stock split to comply with Nasdaq's Minimum Bid Price requirement. As of June 30, 2024, Cingulate had cash and cash equivalents of $0.4 million and total liabilities of $1.9 million, a decrease from the previous year. The company's net loss for the quarter was $3.2 million, a decrease from the $6.6 million loss reported for the same period in 2023, primarily due to reduced R&D and G&A expenses.
On August 13, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, and provided updates on its clinical and business developments. The company reported significant progress with its lead product candidate, CTx-1301, for the treatment of ADHD, including FDA clearance to file for marketing approval and the completion of registration batches, which are essential for a New Drug Application (NDA) submission targeted for the first half of 2025. Cingulate also completed a payer study to assess the market potential for CTx-1301 and raised $1.6 million through a warrant inducement. Additionally, the company executed a one-for-twelve reverse stock split to comply with Nasdaq's Minimum Bid Price requirement. As of June 30, 2024, Cingulate had cash and cash equivalents of $0.4 million and total liabilities of $1.9 million, a decrease from the previous year. The company's net loss for the quarter was $3.2 million, a decrease from the $6.6 million loss reported for the same period in 2023, primarily due to reduced R&D and G&A expenses.
2024年8月13日，生物醫藥公司Cingulate Inc.宣佈截至2024年6月30日第二季度的財務業績，並提供了其臨床和業務發展的最新進展。該公司報告了其ADHD治療的主導產品候選藥CTx-1301的顯著進展，包括FDA清除文件、完成註冊批次等，這是提交新藥申請的關鍵所在，目標是2025年上半年。Cingulate還完成了一項支付者研究，以評估CTx-1301的市場潛力，並通過認股權發放籌集了160萬美元資金。此外，該公司執行了一項一股摺合十二股的股票拆分，以符合納斯達克的最低競買價格要求。截至2024年6月30日，Cingulate的現金及現金等價物爲40萬美元，總負債爲190萬美元，較上年減少。該公司本季度的淨虧損爲320萬美元，較2023年同期的660萬美元減少，主要是由於研發和一般管理費用的削減。
2024年8月13日，生物醫藥公司Cingulate Inc.宣佈截至2024年6月30日第二季度的財務業績，並提供了其臨床和業務發展的最新進展。該公司報告了其ADHD治療的主導產品候選藥CTx-1301的顯著進展，包括FDA清除文件、完成註冊批次等，這是提交新藥申請的關鍵所在，目標是2025年上半年。Cingulate還完成了一項支付者研究，以評估CTx-1301的市場潛力，並通過認股權發放籌集了160萬美元資金。此外，該公司執行了一項一股摺合十二股的股票拆分，以符合納斯達克的最低競買價格要求。截至2024年6月30日，Cingulate的現金及現金等價物爲40萬美元，總負債爲190萬美元，較上年減少。該公司本季度的淨虧損爲320萬美元，較2023年同期的660萬美元減少，主要是由於研發和一般管理費用的削減。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間